Cargando…

Combined Therapy With Avastin, a PAF Receptor Antagonist and a Lipid Mediator Inhibited Glioblastoma Tumor Growth

Glioblastoma multiforme (GBM) is an aggressive, highly proliferative, invasive brain tumor with a poor prognosis and low survival rate. The current standard of care for GBM is chemotherapy combined with radiation following surgical intervention, altogether with limited efficacy, since survival avera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cruz Flores, Valerie A., Menghani, Hemant, Mukherjee, Pranab K., Marrero, Luis, Obenaus, Andre, Dang, Quan, Khoutorova, Larissa, Reid, Madigan M., Belayev, Ludmila, Bazan, Nicolas G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498947/ https://www.ncbi.nlm.nih.gov/pubmed/34630114 http://dx.doi.org/10.3389/fphar.2021.746470

Ejemplares similares

Synergistic Neuroprotection by a PAF Antagonist Plus a Docosanoid in Experimental Ischemic Stroke: Dose-Response and Therapeutic Window
por: Reid, Madigan M., et al.
Publicado: (2022)

DHA modulates MANF and TREM2 abundance, enhances neurogenesis, reduces infarct size, and improves neurological function after experimental ischemic stroke
por: Belayev, Ludmila, et al.
Publicado: (2020)

Integrated inflammatory signaling landscape response after delivering Elovanoid free-fatty-acid precursors leading to experimental stroke neuroprotection
por: Reid, Madigan M., et al.
Publicado: (2023)

Neuroprotectin D1 upregulates Iduna expression and provides protection in cellular uncompensated oxidative stress and in experimental ischemic stroke
por: Belayev, Ludmila, et al.
Publicado: (2017)

Elovanoids are a novel class of homeostatic lipid mediators that protect neural cell integrity upon injury
por: Bhattacharjee, Surjyadipta, et al.
Publicado: (2017)

Blocking pro-inflammatory platelet-activating factor receptors and activating cell survival pathways: A novel therapeutic strategy in experimental ischemic stroke
por: Belayev, Ludmila, et al.
Publicado: (2020)

Superior Neuroprotective Efficacy of LAU-0901, a Novel Platelet-Activating Factor Antagonist, in Experimental Stroke
por: Belayev, Ludmila, et al.
Publicado: (2011)

NPD1 Plus RvD1 Mediated Ischemic Stroke Penumbra Protection Increases Expression of Pro-homeostatic Microglial and Astrocyte Genes
por: Reid, Madigan M., et al.
Publicado: (2023)

Docosahexaenoic Acid Therapy of Experimental Ischemic Stroke
por: Belayev, Ludmila, et al.
Publicado: (2010)

Docosahexaenoic acid improves behavior and attenuates blood–brain barrier injury induced by focal cerebral ischemia in rats
por: Hong, Sung-Ha, et al.
Publicado: (2015)

Multiprong control of glioblastoma multiforme invasiveness: blockade of pro-inflammatory signaling, anti-angiogenesis, and homeostasis restoration
por: Bazan, Nicolas G., et al.
Publicado: (2021)

Acute Treatment with Docosahexaenoic Acid Complexed to Albumin Reduces Injury after a Permanent Focal Cerebral Ischemia in Rats
por: Eady, Tiffany N., et al.
Publicado: (2013)

Docosahexaenoic acid complexed to human albumin in experimental stroke: neuroprotective efficacy with a wide therapeutic window
por: Eady, Tiffany N, et al.
Publicado: (2012)

Docosahexaenoic Acid Signaling Modulates Cell Survival in Experimental Ischemic Stroke Penumbra and Initiates Long-Term Repair in Young and Aged Rats
por: Eady, Tiffany N., et al.
Publicado: (2012)

cRel and Wnt5a/Frizzled 5 Receptor-Mediated Inflammatory Regulation Reveal Novel Neuroprotectin D1 Targets for Neuroprotection
por: Calandria, Jorgelina M., et al.
Publicado: (2022)

Correction to: cRel and Wnt5a/Frizzled 5 Receptor-Mediated Inflammatory Regulation Reveal Novel Neuroprotectin D1 Targets for Neuroprotection
por: Calandria, Jorgelina M., et al.
Publicado: (2022)

PAF‐induced inflammatory and immuno‐allergic ophthalmic diseases and their mitigation with PAF receptor antagonists: Cell and nuclear effects
por: Sharif, Najam A.
Publicado: (2022)

Pharmacokinetics of intravitreal bevacizumab (Avastin(®)) in rabbits
por: Sinapis, Christos I, et al.
Publicado: (2011)

Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects
por: Shamizadeh, Soja, et al.
Publicado: (2014)

Intravitreal bevacizumab (avastin) for circumscribed choroidal hemangioma
por: Mandal, Subrata, et al.
Publicado: (2011)

Using intravitreal bevacizumab (Avastin(®)) – Indian Scenario
por: Kumar, Atul, et al.
Publicado: (2017)

Degradation Characteristics of a Novel PAF Receptor Antagonist, SY0916, in Aqueous Solution
por: Jin, Bo, et al.
Publicado: (2019)

Intravitreal Bevacizumab (Avastin) as an Adjuvant for the Treatment of Posterior Scleritis
por: Lim, Ji Won, et al.
Publicado: (2011)

Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy
por: Shaikh, Saad
Publicado: (2008)

Intravitreal bevacizumab (Avastin) in choroidal neovascular membrane in angioid streaks
por: Sachdev, Nishant, et al.
Publicado: (2007)

Off with the label and on the Avastin bandwagon: Why now and how far?
por: Gopal, K. S. Santhan
Publicado: (2009)

Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture
por: Arevalo, J. Fernando, et al.
Publicado: (2011)

Bevacizumab (Avastin(®)) for the management of anterior chamber neovascularization and neovascular glaucoma
por: Brouzas, Dimitrios, et al.
Publicado: (2009)

Intravitreal Bevacizumab (Avastin) as an Adjuvant Treatment in Cases of Neovascular Glaucoma
por: Ghanem, Asaad A., et al.
Publicado: (2009)

Impact of Intravitreal Injection of Bevacizumab (Avastin) on Rabbit's Choroid and Retina
por: Karawya, Sherif, et al.
Publicado: (2008)

Feasibility of Therapeutic Ultrasound Application in Topical Scleral Delivery of Avastin
por: Almogbil, Hanaa H., et al.
Publicado: (2021)

Intravitreal Bevacizumab (Avastin) as an Adjuvant Therapy for Choroidal Carcinoid Metastasis
por: Karimi, Saeed, et al.
Publicado: (2020)

Endophthalmitis After Intravitreal Bevacizumab (Avastin) Injections: An Outbreak Investigated
por: Shoaib, Khawaja K, et al.
Publicado: (2023)

Functional Consequences of Mutations and Polymorphisms in the Coding Region of the PAF Acetylhydrolase (PAF-AH) Gene
por: Stafforini, Diana M.
Publicado: (2009)

Pulmonary injury after intestinal ischemia and reperfusion injury: effects of treatment with lexipafant, a PAF antagonist
por: Börjesson, A, et al.
Publicado: (1998)

Leyes PAF fiscal, 2008.
Publicado: (2008)

PAF and Haematopoiesis. I. 5-Fluoro-Uracil Induces PAF Production in Haematopoietic Organs of Rats
por: Denizot, Y., et al.
Publicado: (1994)

Intravitreal Bevacizumab (Avastin) Treatment of Neovascular Glaucoma in Ocular Ischemic Syndrome
por: Lee, Sang Joon, et al.
Publicado: (2009)

Acute Bilateral Endophthalmitis Following Bilateral Intravitreal Bevacizumab (Avastin) Injection
por: Tabatabaii, Ali, et al.
Publicado: (2013)

Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
por: Merz, Patrick R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i0ssv45srdqjq4k2mk1ots1rjn